Mineralys makes money moves before looming hypertension approval

Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug. It came with a $1 million upfront fee to the medicine's originator, Tanabe Pharma.

Raccontata daendpoints.news